Supplementary Material for: Perception of a New Prolonged-Release Buprenorphine Formulation in Patients with Opioid Use Disorder: The PREDEPO Study

<b><i>Aim:</i></b> The aim of the study was to assess the acceptance of patients with opioid use disorder (OUD) to switching their opioid dependence treatment (ODT) for a prolonged-release buprenorphine (PRB) injection according to their prior ODT (buprenorphine/naloxone [B/N] or methadone). <b><i>Methods:</i></b> This was an observational, retrospective/cross-sectional, multicentre study of adult patients diagnosed with OUD on ODT. Data collected from diaries were analysed to know their interest and opinion on PRB. Questions with fixed response options were included, and several Likert scales were used. <b><i>Results:</i></b> A total of 98 patients were enrolled (B/N: 50.0%, methadone: 50.0%). The mean age was 46.9 ± 8.43 years and 79.6% were males. PRB was similarly perceived by both groups in most variables analysed, receiving a mean score of 7.2/10 (B/N: 7.4, methadone: 7.0; <i>p</i> = 0.520), and approximately 65% of patients said they were willing to switch to PRB (B/N: 63.3%, methadone: 65.3%; <i>p</i> = 0.833). Of these, a higher percentage in the B/N group considered that switching would be easy/very easy (B/N: 90.3%, methadone: 46.9%; <i>p</i> &lt; 0.001) and that they would start PRB when available (B/N: 64.5%, methadone: 34.3%; <i>p</i> = 0.005). More than 90% would prefer the monthly injection (B/N: 93.6%, methadone: 100%; <i>p</i> = 0.514). One-third of patients in both groups were unsure/would not switch their ODT to PRB (B/N: 36.7%, methadone: 34.7%; <i>p</i> = 0.833). The main reason was administration by injection. <b><i>Conclusion:</i></b> Two-thirds of patients would switch their treatment for PRB, and most patients on B/N considered that switching would be easy. PRB could be a suitable alternative for OUD management.

<b><i>研究目的：</i></b> 本研究旨在评估阿片类物质使用障碍（opioid use disorder, OUD）患者根据其既往阿片类依赖治疗（opioid dependence treatment, ODT）方案（丁丙诺啡/纳洛酮[buprenorphine/naloxone, B/N]或美沙酮），对将当前ODT更换为长效注射用丁丙诺啡（prolonged-release buprenorphine, PRB）的接受度。<b><i>研究方法：</i></b> 本研究为一项针对接受ODT治疗的成年OUD患者的观察性、回顾性/横断面多中心研究。通过分析患者日记收集的数据，以了解其对PRB的关注程度与相关看法；研究纳入固定应答选项的问卷问题，并采用多组李克特（Likert）量表进行评价。<b><i>研究结果：</i></b> 本研究共纳入98例患者（B/N组占比50.0%，美沙酮组占比50.0%），平均年龄为46.9±8.43岁，男性患者占79.6%。两组患者对PRB的多数分析维度评分相近，总体平均得分为7.2/10（B/N组7.4，美沙酮组7.0；p=0.520）；约65%的患者表示愿意更换为PRB（B/N组63.3%，美沙酮组65.3%；p=0.833）。其中，B/N组中认为更换治疗为“容易/非常容易”的患者占比更高（B/N组90.3%，美沙酮组46.9%；p<0.001），且愿意在PRB可供使用时即刻开始治疗的患者占比也更高（B/N组64.5%，美沙酮组34.3%；p=0.005）。超过90%的患者偏好每月一次的注射给药方案（B/N组93.6%，美沙酮组100%；p=0.514）。两组各有三分之一的患者不确定或不愿将自身ODT更换为PRB（B/N组36.7%，美沙酮组34.7%；p=0.833），最主要的拒用原因为注射给药方式。<b><i>研究结论：</i></b> 三分之二的患者愿意更换为PRB治疗，且多数B/N组患者认为更换过程较为简便。长效注射用丁丙诺啡或可成为OUD管理的合适替代方案。